Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...

GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...

Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

Three cell & gene therapy groups - ISCT, ARM & ASGCT - jointly call for 10-year global ban on human germline gene editing, ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

Plus, news about Allogene, Kyverna, Sernova, ADC Therapeutics, Acelyrin, Alumis, Atara, Lava Therapeutics and Repare Therapeutics ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...

Cytokinetics's aficamten outperforms metoprolol in Phase 3 heart disease trial, but FDA approval delayed to December due to ...

Bayer cuts 2,000 jobs in Q1 2025, reaching 11,000 total layoffs amid reorganization. CEO Bill Anderson reports strong pharma ...

Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes ...